Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01909050 · ClinicalTrials.gov registry record
Immune Response in Celiac Disease on In-vitro Gluten Challenge
A clinical trial, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- 42
- Enrollment target
NCT01909050 is a clinical trial that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 42 participants.
The verdict
NCT01909050 has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The main purpose of this study is to see how cells taken from the lining of the intestine behave in the laboratory with exposure to gluten and other substances that act on the immune system. The cells lining the intestine of a person with celiac disease should be different than a person without celiac disease. The study doctors would like to see how the cells react after coming in contact with gluten and if substances that act on the immune system can prevent gluten related inflammation. Examples of these substances include steroids. The cells should produce chemicals of their own in response to the gluten. These other chemicals will be measured and the results compared between those with: * celiac disease that does not respond to a gluten-free diet (refractory celiac disease) * celiac disease which is controlled by a gluten-free diet * uncontrolled celiac disease (either newly diagnosed with celiac disease or not on a gluten-free diet * gluten-sensitivity * disorders other than celiac disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-02 |
| Est. Completion | 2018-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01909050
The ClinicalTrials.gov registry entry for NCT01909050 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01909050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01909050 about?
NCT01909050 is a clinical study titled "Immune Response in Celiac Disease on In-vitro Gluten Challenge". The main purpose of this study is to see how cells taken from the lining of the intestine behave in the laboratory with exposure to gluten and other substances that act on the immune system. The cells lining the intestine of a person with celiac disease should be different than a person without celi...
What is the current status of trial NCT01909050?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2013-02. Estimated completion is 2018-03.
Who is sponsoring clinical trial NCT01909050?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.